A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma
KCP-330-017 (STOMP)
NCT02343042
 Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
Myeloma |
Dr. Marc Lalancette
Diane Bernard
418-525-4444 poste 15782
Patricia Chabot
418-525-4444 poste 15769
|
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma
SUCCESSOR-1
NCT05519085
Recruiting
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Myeloma |
Dr. Marc Lalancette
Patricia Chabot
418-525-4444 poste 15769
|
A Randomized, 2-Arm, Phase 3 Study of Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
MagnetisMM-7 (C1071007)
NCT05317416
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Myeloma |
Dr. Jean-Samuel Boudreault-Pedneault
Marie-Anne Capobianco
514-338-2222 poste 3493
|
A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects With Relapsed or Refractory Multiple Myeloma
SUCCESSOR-01/CA057-001
NCT05519085
Recruiting
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Myeloma |
Dr. Jean-Samuel Boudreault-Pedneault
Maia Labelle
514-338-2222 poste 2818
|
A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants With Relapsed or Refractory Myeloma Who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide
MonumenTAL-6
NCT06208150
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Jean-Sébastien Claveau
Marie-Pier Lecours-Cyr
514-252-3400 poste 5037
|
A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
MajesTEC-9
NCT05572515
Recruiting
|
CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL
PAV. MAISONNEUVE/PAV. MARCEL-LAMOUREUX
|
Myeloma |
Dr. Richard Leblanc
Marie-Pier Lecours-Cyr
514-252-3400 poste 5037
|
A Randomized, 2-Arm, Phase 3 Study of Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease-Positive After Undergoing Autologous Stem-Cell Transplantation
MagnetisMM-7 (C1071007)
NCT05317416
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
A Phase 3, Randomized, Open-Label Study to Compare the Efficacy and Safety of Anitocabtagene Autoleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Multiple Myeloma
iMMagine-3
NCT06413498
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma
TED18162
NCT06630806
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
Elranatamab post trial access: an open-label, single-arm study for participants with multiple myeloma continuing from Pfizer-sponsored Elranatamab clinical studies
MagnetisMM15
NCT06057402
Recruiting
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Myeloma |
Dr. Chaim Shustik
Dr. Michael Sebag
Nancy Renouf
514-934-1934 poste 35718
|
Groupe d'étude en oncologie du Québec